We serve Chemical Name:cyclobutancarbonylchlorid CAS:5006-22-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:cyclobutancarbonylchlorid
CAS.NO:5006-22-4
Synonyms:Cyclobutane-1-carbonyl chloride;MFCD00001319;EINECS 225-680-8;Chlorure de cyclobutanecarbonyle;cyclobutancarbonylchlorid;Cyclobutanecarbonyl chloride;Cyclobutanecarbonylchloride
Molecular Formula:C5H7ClO
Molecular Weight:118.562
HS Code:2916209090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:134.7±0.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.486
PSA:17.07000
Exact Mass:118.018539
LogP:1.39
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2920 8/PG 2
Packing Group:II
Contact us for information like Cyclobutane-1-carbonyl chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Cyclobutanecarbonylchloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00001319 Use and application,Cyclobutanecarbonyl chloride technical grade,usp/ep/jp grade.
Related News: Toxic forever chemicals have no place in personal care products,” Scott Faber, EWG’s senior vice president of government affairs. “PFAS have been linked to serious health problems, including cancer and harm to the reproductive and immune systems. EWG applauds Sen. Collins and Rep. Dingell for introducing the No PFAS in Cosmetics Act. cyclobutancarbonylchlorid manufacturer Toxic forever chemicals have no place in personal care products,” Scott Faber, EWG’s senior vice president of government affairs. “PFAS have been linked to serious health problems, including cancer and harm to the reproductive and immune systems. EWG applauds Sen. Collins and Rep. Dingell for introducing the No PFAS in Cosmetics Act. cyclobutancarbonylchlorid supplier Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. cyclobutancarbonylchlorid vendor Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. cyclobutancarbonylchlorid factory Javier Valero-Elizondo, M.D., M.P.H., from the Houston Methodist DeBakey Heart and Vascular Center in Texas, and colleagues compared FT for individuals with ASCVD only, cancer only, both ASCVD and cancer, and neither ASCVD nor cancer using data from the National Health Interview Survey.
